Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGIV-C for symptomatic generalized myasthenia gravis
2014-003997-18Phase 2Completed
- Sponsor
- Grifols
- Start
- May 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myasthenia gravis (MG) comparing IGIV-C with Placebo (2 arms). Primary endpoint: Mean change in Quantitative Myasthenia Gravis score from baseline to Week 24. Started May 2015; status: completed.
02
Drugs
gamunex
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2014-003997-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003997-18.